Search Results - "Fiddian, A P"

Treatment of Acute Herpes Zoster: Effect of Early (< 48 h) versus Late (48–72 h) Therapy with Acyclovir and Valaciclovir on Prolonged Pain by Wood, M. J., Shukla, S., Fiddian, A. P., Crooks, R. J.

“…The efficacy of early versus late treatment with acyclovir and valaciclovir on zoster-associated pain was assessed from two databases (1076 patients) that were…”
Get full text

Clinical Efficacy of High-Dose Acyclovir in Patients with Human Immunodeficiency Virus Infection: A Meta-Analysis of Randomized Individual Patient Data by Ioannidis, John P. A., Collier, Ann C., Cooper, David A., Corey, Lawrence, Fiddian, A. Paul, Gazzard, Brian G., Griffiths, Paul D., Contopoulos-Ioannidis, Despina G., Lau, Joseph, Pavia, Andrew T., Saag, Michael S., Spruance, Spotswood L., Youle, Michael S.

“…A meta-analysis of 8 randomized trials (1792 patients, 2947 patient-years of follow-up) showed that acyclovir (⩾3200 mg/day) offered a significant survival…”
Get full text

Phase specific analysis of herpes zoster associated pain data: a new statistical approach by Arani, Ramin B., Soong, Seng-Jaw, Weiss, Heidi L., Wood, Martin J., Fiddian, Paul A., Gnann, John W., Whitley, Richard

“…Herpes zoster or shingles is a frequent occurrence in both elderly individuals and immunocompromised hosts. The pain associated with herpes zoster is the most…”
Get full text

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation by SELBY, P. J, POWLES, R. L, EASTON, D, PERREN, T. J, STOLLE, K, JKAMESON, B, FIDDIAN, A. P, TRYHORN, Y, STERN, H

“…Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6…”
Get full text

A randomized controlled trial of acyclovir versus netivudine for treatment of herpes zoster by SÖLTZ-SZÖTS, J, TYRING, S, ANDERSEN, P. L, LUCHT, R. F, MCKENDRICK, M. W, DIAZ PEREZ, J. L, SHUKLA, S, FIDDIAN, A. P

“…Oral acyclovir has become the standard of care for treatment of acute herpes zoster. Netivudine is a novel antiviral with greater in-vitro activity against…”
Get full text

Topical acyclovir in the management of recurrent herpes labialis by Fiddian, A P, Ivanyi, L

“…A double-blind, randomized, placebo-controlled trial of 5% acyclovir ointment was carried out for thirty-one episodes of herpes labialis in thirteen patients…”
Get more information

Successful Treatment Of Herpes Labialis With Topical Acyclovir by Fiddian, A. Paul, Yeo, Jane M., Stubbings, Ronald, Dean, Donald

“…A double blind, placebo controlled trial of 5% acyclovir cream, applied topically five times a day for five days, was carried out in 49 patients with recurrent…”
Get full text

Prophylactic oral acyclovir after renal transplantation by Pettersson, E, Hovi, T, Ahonen, J, Fiddian, A P, Salmela, K, Höckerstedt, K, Eklund, B, von Willebrand, E, Häyry, P

“…In a double-blind, controlled study 35 herpes simplex virus (HSV) antibody-positive patients were randomized to receive oral acyclovir 200 mg X 4 daily or…”
Get more information

Antiviral developments. Three new drugs approved for treatment of HIV infection by Fiddian, A P

Get full text

Antiviral developments by Fiddian, A. P.

Get full text

Antiviral developments by Fiddian, A. P.

Get full text

Antiviral developments by Fiddian, A.P.

“…Zanamivir, the first of a new class of antivirals active against both influenza A and B viruses, has now received wide regulatory approval in the European…”
Get full text

Acyclovir: an update of the clinical applications of this antiherpes agent by Fiddian, A P, Brigden, D, Yeo, J M, Hickmott, E A

“…This paper reviews the clinical evaluation of acyclovir in the treatment of herpes-virus infections, predominantly those due to herpes simplex and…”
Get more information

Prevention of herpes simplex virus infections in susceptible patients by FIDDIAN, A. P

“…Immunocompromised patients are at high risk of developing herpes simplex virus infections caused by reactivation of the virus. Intravenous and oral…”
Get full text

Prophylactic oral acyclovir in recurrent genital herpes by Mindel, A, Weller, I V, Faherty, A, Sutherland, S, Hindley, D, Fiddian, A P, Adler, M W

“…56 patients with frequently recurring genital herpes were treated in a randomised double-blind trial with either oral acyclovir 200 mg four times a day or…”
Get more information

Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study by Halsos, A M, Salo, O P, Lassus, A, Tjøtta, E A, Hovi, T, Gabrielsen, B O, Fiddian, A P

“…A randomised, double-blind, placebo-controlled, crossover study was conducted in 31 male patients with a history of frequently recurrent genital herpes who…”
Get more information

Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial by Thin, R N, Jeffries, D J, Taylor, P K, Ayra, O P, Rodin, P, Yeo, J, Fiddian, A P

“…Eighty-eight of 111 patients with frequently recurring genital herpes attending five centres completed a randomized, double-blind, cross over trial with 200 mg…”
Get more information

Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter by Cooper, David A, Gatell, Jose M, Kroon, Susanne, Clumeck, Nathan, Millard, Judith, Goebel, Frank-D, Bruun, Johan N, Stingl, Georg, Melville, Rex L, Gonzalez-Lahoz, Juan, Stevens, John W, Fiddian, A. Paul

“…When our European-Australian Collaborative Group study was initiated, zidovudine had been shown to provide clinical benefit in patients with the acquired…”
Get full text

Acyclovir in first attacks of genital herpes and prevention of recurrences by Mindel, A, Weller, I V, Faherty, A, Sutherland, S, Fiddian, A P, Adler, M W

“…Sixty women patients experiencing a first attack of genital herpes were randomly treated with either oral acyclovir for 42 days or oral acyclovir for five days…”
Get full text

Three new drugs approved for treatment of HIV infection by Fiddian, A P

“…The armamentarium of anti-HIV therapies has been notably increased in the past few months by the marketing approvals granted to abacavir, efavirenz and…”
Get full text